The Food and Drug Administration proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list.

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO) now offers a more compelling setup than GLP-1 category leader Eli Lilly (NYSE:LLY) after a peak-to-current decline of roughly 68% from Novo’s mid-2024 high near $127 to recent levels near $40.

Novo Nordisk A/S upgraded to Hold as FDA tightens compounded GLP-1s;Hims & Hers Health, Inc. stays Buy. Click for this NVO and HIMS stock comparison and update.

Novo Nordisk (NYSE:NVO) is advancing the launch of an oral version of Ozempic, expanding its GLP-1 diabetes franchise beyond injectable formats. The company is also seeking regulatory approvals to extend Ozempic use to pediatric patients.

Novo Nordisk A/S is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs.

Novo Nordisk (NVO) stock surged over 6% after FDA proposed removing weight-loss drugs from compounding list, hitting highest level in two months.

Novo Nordisk (NYSE:NVO) has drawn investor attention after recent share price moves, with the stock showing a monthly gain alongside weaker past 3 months and 1 year total returns, prompting closer examination of its fundamentals.

Novo Nordisk CEO Mike Doustdar sits down with CNN to discusses manufacturing Wegovy pill in the U.S, direct to consumer weightloss drugs, competition and Iran war

The pharmaceutical industry has rarely seen a stock rise as spectacularly as Novo Nordisk (NVO 0.69%) did during the GLP-1 boom, only for it to plummet and surrender more than two

Jan 12 (Reuters) - Novo Nordisk ‌CEO Mike Doustdar said on Monday as ‌many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives have captured a ...